Business Wire

ABS and Persona AI Partner to Bring Humanoid Robotics to Shipyards, Advancing Safety and Productivity

24.9.2025 00:01:00 CEST | Business Wire | Press Release

Share

A groundbreaking collaboration to develop inspection technologies for Persona AI’s humanoid robot platform that enhances productivity and safety in shipyards was formalized today with the signing of an MOU between ABS and Persona AI.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250923457571/en/

Conceptual image is courtesy of Persona AI

The initiative will focus on adapting Persona AI’s humanoid robots, based in part on NASA’s robotic hand technology, for a range of shipyard tasks. Unlike traditional industrial robots, humanoid robots are uniquely suited to operate in shipyards designed for human workers, offering flexibility and mobility in complex, confined, or ergonomically challenging spaces.

Under the MOU, ABS and Persona AI will collaborate on a series of joint development projects, collecting data to support classification during ship construction.

Ultimately, it will support development of new ABS standards for the types and quality of data required to support digital and remote survey techniques. These standards will not only guide future robot design but also help understand how to collect, evaluate, and apply robotic data for certification and compliance purposes.

“ABS is proud to lead the way in advancing the safe integration of emerging technologies into the maritime industry,” said John McDonald, ABS President and Chief Operating Officer. “This collaboration with Persona AI reflects our commitment to innovation and safety, as we work to establish the standards and protocols that will enable humanoid robots to perform complex tasks reliably and securely in shipyard environments. By combining cutting-edge robotics with ABS’s deep expertise in certification and safety, we’re helping shape a smarter, safer future for shipbuilding.”

This marks a defining moment for the shipbuilding industry,” said Nic Radford, CEO and Co-Founder of Persona AI. “Partnering with ABS, the global authority on maritime standards, demonstrates that humanoid robotics are no longer a distant concept but on a path toward certified reality, set to transform how this industry builds, innovates, and competes.

The project will leverage ABS’ extensive investment in AI evaluation of data and data quality. A copy of Verification and Validation of Models, Simulations, and Digital Twins is available to download here.

ABS is a world leader in supporting the development and application of technology innovation at sea. More information is available here.

About ABS

ABS, a global leader in classification services, is focused on delivering a safer, cleaner future for the marine and offshore industries. For over 160 years, ABS has been setting standards for safety and excellence and continues to innovate in the fields of clean technology, digitalization and artificial intelligence, providing industry-leading technical advisory services. With a global network of surveyors, engineers, technology specialists and support staff, ABS works with industry leaders including its members and clients around the world to improve safety in operational performance and efficiency with innovative solutions for the complete life cycle of marine and offshore assets.

About Persona AI

Persona Al, a pioneering robotics company headquartered in Houston, Texas, is at the forefront of developing intelligent humanoid robots specifically designed for a wide array of industrial applications. Established in 2024, Persona Al leverages a rich heritage of expertise, drawing from decades of experience in crafting sophisticated robotics for demanding environments, including space and deep-ocean exploration. This unparalleled background enables the company to address real-world labor challenges with innovative and robust solutions. Learn more at www.personainc.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250923457571/en/

Contacts

For more information, contact ABS Media Relations: jmire@eagle.org

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye